Deciphera Pharmaceuticals, Inc. to Present Data from DCC-3014 and Ripretinib Programs at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting
Deciphera Pharmaceuticals, Inc. (DCPH)
Last deciphera pharmaceuticals, inc. earnings: 3/9 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
deciphera.com/investor-relations
Company Research
Source: Business Wire
- Preliminary Anti-tumor Activity Observed in Initial Diffuse-type TGCT Patients Treated with DCC-3014 in Ongoing Phase 1 Study -- DCC-3014 was Generally Well Tolerated with No Reported Grade 3 or Higher TEAEs in Initial Diffuse-Type TGCT Patients -- Encore Presentation of Results from the INVICTUS Pivotal Phase 3 Study of Ripretinib in Advanced GIST to be Featured in Oral Presentation Session - WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced preliminary data from the ongoing Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, including initial data in diffuse-type tenosynovial giant cell tumor (TGCT) patients as well as an encore presentation of the INVICTUS pivotal Phase 3 study of ripretinib, a broad-spectrum KIT and PDGFRa inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST). Results from these programs will be presented at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting being held Novemb
Show less
Read more
Impact Snapshot
Event Time:
DCPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCPH alerts
High impacting Deciphera Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
DCPH
News
- Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth [Yahoo! Finance]Yahoo! Finance
- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) had its price target raised by analysts at JPMorgan Chase & Co. from $14.00 to $16.00. They now have a "neutral" rating on the stock.MarketBeat
- Nimble Therapeutics Adds Peptide Drug Development Expertise to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 20.8% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Zenas BioPharma Appoints Patricia Allen to its Board of Directors [Financial Post (Toronto, Ontario, Canada)]Financial Post
DCPH
Earnings
- 2/6/24 - Beat
DCPH
Sec Filings
- 2/20/24 - Form 4
- 2/20/24 - Form 4
- 2/20/24 - Form 4
- DCPH's page on the SEC website